Hello, everyone, and welcome to the Signify Health Q3 2021 earnings conference call. My name is Seb, and I'll be the operator for your call today. There will be an opportunity to ask questions, and if you wish to submit a question, please press star one on your telephone keypad. If you change your mind and wish to withdraw your question, please press star two. I will now hand the floor over to Jennifer DiBerardino, Head of Investor Relations and Treasurer. Please go ahead. Good morning, and welcome to Signify Health's Q3 2021 earnings conference call. This call is being webcast live and a recording will be available on the events page of our investor website at signifyhealth.com through January 10, 2022. Throughout the call this morning, we will be referencing the financial tables that appeared in our press release dated November 9, 2021. In addition, the Q3 earnings call summary slide presentation we have posted to the events page of the IR website. This morning, we will discuss Signify Health's business outlook, and we will also make certain statements about our future performance, including projections about our future financial performance, our anticipated growth strategies, anticipated trends in our business, and our outlook, including estimates for total GAAP revenue, total adjusted EBITDA, in-home evaluations, program size, and weighted average savings rate. These statements are only predictions based on our current expectations and projections about future events and constitute forward-looking statements within the meaning of the federal securities laws. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially from the results, level of activity, performance, or achievements expressed or implied by the forward-looking statements. Please note the cautionary language about our forward-looking statements as presented in our earnings press release and in our quarterly report on Form 10-Q, which will be filed later today. That same cautionary language applies to the statements made in this conference call. We will also discuss certain non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA margin. Reconciliations to the relevant GAAP numbers for these non-GAAP measures are included in the earnings release filed on Form 8-K yesterday and also in our Form 10-Q, which will be filed later today. As a reminder, we intend to participate in industry or sell-side sponsored conferences. In lieu of issuing a press release to announce each conference, we will be posting our conference attendance on the events page calendar of our investor relations site at signifyhealth.com. I encourage you to register for alerts on the investor site so that you receive an email notification each time we add a conference, other event, or other updates to the IR calendar. Joining me on the call today are Kyle Armbrester, Chief Executive Officer, and Steve Senneff, President and Chief Financial Officer. Kyle will provide a business overview, followed by Steve with a financial overview. We will have an operator-facilitated question and answer session after our prepared remarks. Now I will turn the call over to Kyle. Thank you, Jennifer. Good morning, and thank you for joining us. Our Q3 and year-to-date performance reflects progress towards our mission of activating the home for care and enabling the shift to value-based care. Our current strategic focus is expanding to as many unique homes as possible. We also build diversified service offerings that help to identify and close care gaps and drive better patient outcomes. Yesterday evening, we announced strong financial results for the Q3 and first nine months of 2021. Through September, revenue grew by 42% to $592 million, and adjusted EBITDA increased 52% to $131 million from the nine-month period a year ago, largely driven by in-home evaluation or IHE volume growth in our Home and Community Services segment. In the first nine months of the year, we performed over 1.4 million IHEs, exceeding the number performed for the full year 2020. Our 2021 results to date are driving positive momentum into 2022, with continued in-home demand expected to fuel HCS growth, diversification of our services in the home, and our episode weighted average program size moving from approximately $5 billion-$6 billion next year. Given this performance, we are projecting 20%+ top line growth in 2022 and corresponding adjusted EBITDA growth, which is expected to benefit from improving operating leverage. Clients are increasingly asking us for expansion of our transition to home and analytics services for their other value-based programs, which we view as another positive trend. A testament to our value of our in-home evaluations, we have received new customer commitments for IHE volume that will continue to drive substantial growth momentum into 2022. We have seen several notable clients move and expand volume to Signify and away from legacy or insourced programs, realizing the value that we bring to their members. We remain confident in our belief that the risk of insourcing our space is low, given our unique data and analytics platform, nationwide clinical network, member density, and our strong customer relationships. As we look ahead to future years, we are very bullish about our HCS business. The value of our in-home evaluations for both our customers and Medicare Advantage members who receive IHEs at no cost has increased tremendously. We are doing more in the home than ever for our clients by helping to connect their members back into the health system each and every day. We also have made substantial progress on the social determinants of health front, connecting members more than 390,000x with social services in their community. We are working to connect members, many of whom have not been under the regular care of a provider, back to a primary care physician in their community and even scheduling appointments when possible. We provide the PCP a comprehensive summary of their patient's clinical and social evaluation, highlighting issues that require attention. In fact, approximately 72% of members who receive an IHE from Signify Health return to an outpatient care setting within a year after their IHE. While our doctors and nurse practitioners are in the home, they perform various screenings to help close care gaps. We are proud to have earned the National Committee for Quality Assurance, or NCQA, Healthcare Effectiveness Data and Information, or HEDIS certification for several of our in-home screening services such as diabetic eye exams, diabetic kidney disease monitoring, colorectal cancer screening, and osteoporosis management in women. Test results are also shared with the member, the plan, and the respective primary care physician to provide another data point for any identified health issues and appropriate treatment plans. We continue to successfully expand our clinician network to support our growing IHE volume despite recent concerns in other parts of the industry around the difficulty of hiring healthcare workers. While we have seen some capacity challenges in certain geographic areas, a significant benefit of our flexible network is that we credential our providers in multiple states, allowing us to deploy them wherever evaluation demand requires, including rural communities. Our model and technology make it easy for providers to do what they value most, spend quality time with patients, instead of dealing with administrative issues in a facility setting. As a result, we believe we have not experienced the same clinician staffing issues as reported by some others in the industry. Using the home as a key venue to activate the care journey, we believe coordination of care will be one of our strategic pillars going forward. Our future service expansion includes medication management, chronic condition management, remote patient monitoring, and follow-on services to improve the health and well-being of beneficiaries. Almost all of our customers are asking for this expansion of our work, realizing the value of our engagement in their members' lives while in their homes. This represents a tremendous opportunity for us to expand our in-home market share and continue to diversify into new services to drive better outcomes for the millions of lives we touch annually. We have frequent conversations with our plan customers and regulatory and legislative constituents about the current state of, and the future vision for, healthcare in the United States generally, and the Medicare Advantage program specifically. Medicare Advantage is an important program providing about 27 million individuals high-quality care with better benefits at a lower beneficiary cost when compared to Medicare fee-for-service. We believe that the risk adjustment process, with all the appropriate checks and balances, is critical to the functioning of value-based care and Medicare Advantage. Appropriate risk adjustment, including in-home evaluations, levels the playing field to provide broad and equitable access to care for the most vulnerable MA members. As I've outlined this morning, the value of our IHEs to our customers and Medicare Advantage members is tremendous and is an essential service that provides insights, coordination, and critical member touch points. We have a roadmap to expand our capabilities in the home as we focus on opportunities to support our clients in their efforts to address health disparities to ensure health equity moving forward. We believe there will be further adoption of value-based payment programs in Medicare, Medicaid, and across the entire health system. Currently, approximately 40% of Medicare fee-for-service payments, 30% of commercial payments, and 25% of Medicaid payments are made through some sort of value-based arrangement. As we advance value-based payment models through our excellent work in both our Home and Community Services and Episodes of Care services, we expect Signify Health to be a significant part of this movement. In Episodes of Care, we are the largest convener in the CMS bundled payment program today, and as such, meet regularly with CMMI to provide feedback through thought leadership on the current BPCI-A program and its future state. We look forward to the next iteration of the BPCI-A program and believe that it will likely have a mandatory aspect. Liz Fowler, the head of CMMI, recently spoke publicly at a briefing hosted by the Alliance for Health Policy and indicated that CMMI is actively engaged in exploring bundled payments that go beyond post-acute care to move upstream to engage specialists in managing patients to avoid and/or reduce acute events. This focus nicely dovetails with our non-BPCI-A Episodes of Care, where we can support not only procedure-based bundles, but also conditions such as maternity, diabetes, and substance abuse. We are continuing our focus on diversification of revenue through continued discussions related to ACO programs and other targeted models like radiation oncology. We continue to make successful inroads in our non-BPCI-A business. In October, we jointly announced with our customer, the State of Connecticut, that their program was approved by CMS as an all-payer advanced alternative payment model. This is an important designation for the Episodes of Care payment model administered by Signify through our networks of distinction. Eligible services included in these programs could span as much as 60% of the average health plan spend and include episodes such as knee replacement, colonoscopy, cataract surgery, care related to pregnancy, and more. CMS' ongoing efforts and commitment to affordability, quality, and outcomes has been of significant benefit to patients, providers, and taxpayers alike. We are excited that the best practice from federal value-based programs will be extended to commercial health plans, and we are proud to be a part of this catalyst for continued adoption of value-based care by innovative provider organizations. In closing, we are pleased with our Q3 and year-to-date results. Our long-term vision is to drive positive outcomes for our partners and their members as a platform for value-based care. We simplify participation in highly complex payment programs and enable health plans and health systems to successfully transition to value-based payments. Over time, we may supplement our strong capabilities with acquisitions or partnerships with other companies to add further functionality and innovation to our platform to drive increased value for our customers and for patients. I will now turn the call over to Steve to walk you through the Q3 and year-to-date financial results. Thanks, Kyle. Good morning, everyone. Strength in our Home and Community Services segment is driving our strong performance in the Q3 and year to date. In Episodes of Care services, we continue to deliver strong savings to our partners across the BPCI program while ensuring individuals receive excellent care within their episodes. Results for ECS in the Q3 were in line with our expectations as we await the next BPCI program reconciliation in the Q4. During my commentary, I will be referring to the tables that appeared in the earnings press release issued yesterday, as well as the earnings presentation on the events page. As you can see in Table 1, we had total revenue in the quarter of $199.2 million, an increase of 29% when compared to the same period last year. Revenue strength in the quarter was primarily driven by HCS growth of 47% to $169.1 million. Total evaluation volume for the Q3 was approximately 488,000, including virtual evaluations. Virtual evaluations as a percentage of total evaluations continued to decline through the first nine months of 2021, reflecting customer preference to perform the evaluations in the home. Although we saw an uptick in September in certain geographic regions, which we attribute to local COVID spikes. HCS segment services also include diagnostic and preventative testing services, and we continue to see attachment rates increase. As a reminder, we expect Q4 IHE volume to be in line with historical patterns as the lowest quarter of the year and to be lower year-over-year comparison from the 2020 Q4 due to last year having the COVID-related catch-up as we have previously discussed. Still on Table 1, Q3 2021, ECS revenue was $30.1 million, a 25% decline compared to the same period last year. The decline was related to the adverse impact of COVID-19 on program size and our savings rate. Additionally, we recognized $9.2 million of revenue in the Q3 of 2020 related to new information received ahead of the reconciliation due in the Q4 of 2020. The new information received reflected the impact of COVID-19 on BPCI program size and the subsequent CMS imposed changes offered to providers that had an overall beneficial impact on savings rates. As I mentioned, we will receive the next BPCI reconciliation in the Q4, which will reflect bundle performance primarily from the first half of 2021. As we discussed last quarter, we continue to monitor patient case mix adjustments and the next set of care issues with skilled nursing facilities, and we'll have more information when we receive the next reconciliation and report on it with our year-end results. Our data indicates that utilization continued to improve in the Q3 despite the prevalence of the COVID-19 Delta variant. We remain on track to end the year at a $6 billion run rate for program size, setting our episodes business up for a strong 2022. Moving to table four, total company adjusted EBITDA for the Q3 increased 46% to $42 million compared to $28.7 million for the Q3 of 2020, driven primarily by the strong growth in Home and Community Services. Back to table one. Q3 total net income was $29.3 million compared to a loss of $13.3 million for the same period a year ago. Net income attributable to Signify Health was $20.2 million in the Q3 of 2021 or $0.12 per share on a fully diluted weighted average share basis. There is no meaningful year-ago comparison due to the IPO and subsequent reorganization in February 2021. Our strong operating performance, in addition to the $27.3 million quarterly reevaluation of our equity appreciation rights, or EARs, drove net income this quarter. We marked the EARs to market each quarter, and the credit in the quarter reflects the current lower value of our stock price. Even excluding the impact of the EARs, we achieved positive net income in the Q3, an encouraging sign of the trajectory we are on. Year-to-date results through September 30, 2021, largely reflect the continued overall strength in our Home and Community Services segment, with strong IHE volume for the first nine months of 2021 of over 1.4 million. As I mentioned, we did see a slight uptick in virtual IHEs in September, but we still expect virtual evaluations as a percentage of total IHE volume to continue to be lower than 2020 pandemic levels. Episodes of Care services results for the first nine months of 2021 continue to reflect the COVID-19 impact on healthcare utilization, savings rate, and discharge patterns reported in connection with the reconciliation received in June. Moving on, as you can see in table two, we ended the quarter with $678.8 million in unrestricted cash, an increase from the Q2 primarily related to cash receipts from the Q2 BPCI reconciliation. We ended the quarter with debt outstanding of $350 million and $173 million in capacity under our new revolving credit facility. Given our strong cash position at September 30, 2021, which exceeds our debt levels, we ended the period with negative net leverage. Given our strong results for the nine months ended September 30, 2021, we are raising total revenue and adjusted EBITDA guidance ranges for 2021 as follows: Total GAAP revenue in the range of $755 million-$770 million and total adjusted EBITDA in the range of $160 million-$170 million. We are providing updated estimates for our key performance indicators for the full year 2021. Reflecting continued strength in Home and Community Services, we now expect IHEs in the range of approximately $1.815million-$1.855 million. Reflecting the ongoing impact of COVID-19 on Episodes of Care services, we are maintaining our estimates of ECS segment weighted average program size of approximately $4.9 billion-$5.1 billion, and ECS segment weighted average savings rate of approximately 6.1%-6.4%. Referring to slide six in our Q3 earnings presentation, I would like to point out that when we gave guidance for 2021 in March of this year, we were projecting about 20% revenue growth. With our updated 2021 guidance, it could now be as high as 25%. As Kyle mentioned, we are looking at strong top-line momentum heading into 2022, with expectations for overall 20%+ revenue growth and corresponding adjusted EBITDA growth, which is expected to benefit from improving operating leverage. Taken altogether, this is a testament to the incredible work done across the company. We plan to provide detailed 2022 guidance on our Q4 2021 earnings call. Now, I'd like to turn the call back to Kyle for closing remarks. Thanks, Steve. I would like to take this opportunity to thank our team at Signify for their positive and compassionate focus on the individuals we serve. Signifiers consider the whole person when helping health plans and providers close gaps in care so that people can remain in their homes and enjoy more healthy, happy days. As I've mentioned, our current strategic focus is expanding to as many unique homes as possible, while we also build diversified service offerings that help to identify and close care gaps and drive better patient outcomes. I would also like to thank all of our stakeholders who are on this journey with us for the value we expect to generate over the long term. Now, I'll turn the call over to the operator to take your questions. Operator? Thank you. As a reminder, if you would like to ask a question, please press star one on your telephone keypad. If you change your mind and wish to withdraw your question, please press star two. Our first question comes from Anne Samuel at J.P. Morgan. Please go ahead. Hi, guys. Congrats on the great quarter and thanks for taking the question. Really appreciated the color on 2022 growth expectations. I was hoping maybe you could provide a little bit more color about what headwinds and tailwinds are included within those assumptions. Yeah, it's Steve. Yeah, we typically I wouldn't guide to 2022 this early, but we just see, you know, tremendous momentum. I'd say the two big things are we've seen a lot of momentum on IHE volume. As we look into next year, we have a lot of visibility. We're doing all that planning today with our plan members or the plan payers. Then also, the confidence we have in having the $6 billion-plus exit run rate for ECS. When you combine those two, we felt confident that we could lean in and give a little bit of a signal that we feel like we're gonna have another great year in 2022. That's great. Maybe just a follow-up to that, how should we be thinking about, you know, some of the labor inflation impact on your savings rate, as we think about next year? The labor rate, are you talking about just labor rate inflation that other companies are facing 'cause that's not really a savings rate. Exactly. Yeah, I guess maybe more impact on margin. Yeah. Yeah. Yeah. Look, you know, one of the things we have, advantage, you know, you hear a lot of companies saying that they're having a lot of pressure on that. I think the uniqueness of our network today allows us to avoid some of those same challenges that other companies are having. We've continued to maintain a very strong network. You know, our biggest challenge is just the growth. The growth is so significant, making sure that we keep up with that. There's a few markets that we, you know, have had to make sure that we can deliver in those markets. But the flexibility has always been we've got, physicians and nurse practitioners are credentialed across different markets that allow us the flexibility to move people around. That's a big advantage that we have. Great. Thank you. Our next question comes from Michael Cherny from Bank of America. Please go ahead. Good morning. Thanks for taking the question. Maybe just to follow up again on the 2022 numbers, and I know, Steve, as you mentioned, this typically isn't when you give a lot of color, but I just wanna make sure I understood Kyle's comments correctly regarding EBITDA. I couldn't really tell, are you expecting EBITDA margins to expand next year? Is EBITDA, at least on the preliminary side, expected to grow in line with or ahead of revenue based on what you see currently? Yeah. Michael, fair question. Like I said, we're gonna save all the details for the next quarter. Yes, what we're signaling is 20%+ top line growth we're comfortable with. You know, our model as we continue to grow, we do have room for EBITDA expansion as well as investing back in the business. It's a nice part of our business model is we can do both. Got it. I I just wanna make sure I heard the comments correctly, and that's helpful. I guess intra-quarter, obviously the OIG report came out that had some questions about the market as a whole. I know that the company's been very vocal in putting forward their explanation. I think in this venue as well, we'd just love to hear a little bit more about your reaction, you know, Kyle, Steve, to the OIG report and why Signify is differentiated versus some of the commentary that was made and some of the approaches that were taken relative to the view of the Medicare Advantage carriers that were noted in the report. Yeah, absolutely Michael, happy to take it. The most recent report that came out really wasn't anything new, and it was focused on 2016 data, and it was largely the same as the report that they put out in 2020. They were pretty consistent. What they were really focused on more than anything was MA plan oversight. I would just share they were obviously focused on a single plan and what that plan was doing back in 2016 was groundbreaking and innovative, and it's become commonplace throughout the industry now, right? This whole notion that you know there's any gamesmanship or anything I think is totally unfounded, number one. Number two, the big recommendation from the report, which we've been doing for a long time, is just when you're touching MA members or you're going in and identifying conditions or closing care gaps, is to make sure that you're reconnecting them to care, both social and clinical. We spend a lot of time sending medical records to primary care doctors, getting appointments booked so folks can get back to see a specialist or a primary care doctor. As you know, we mentioned in the script, we've closed over 390,000 social condition issues. Those could be food shortage issues, transportation. I think it's actually the fact that in-homes exist for the Medicare Advantage population is remarkable, right? They're provided for free to the beneficiaries. We go in and do, as I just mentioned, a battery of different work. You know, the other thing I would say is our model is really absent moral hazard, right? Our clinicians go in and get paid the same amount of money regardless of the work that they do inside the home. Our whole focus is on activating and getting those folks reengaged in their care. So many of them haven't seen a primary care doctor in a long time, have a lot of chronic conditions that are going unmanaged. Typical fee for service ignores them, right? Typical fee for service waits until they show up in the emergency room or, you know, run into a negative health outcome. What's the beauty of Medicare Advantage and the model that we've brought forward and that so many of our plan clients are deeply engaged in, is it's genuine preventative medicine, right? We're moving away from just sick care in this country, and instead taking care of folks and making sure that their conditions and diseases are being managed more appropriately. The last point I would make, you know, while the report focused on risk adjustment, that is a very small percentage of the total work that we do inside the home, right? As I mentioned, we're doing chronic condition management, a battery of gaps in care closure, closing out social determinants of health issues, and we're super proud of that. We've done that, you know, and the other beauty of Medicare Advantage, it extends to rural markets and really helps solve a bunch of health equity issues, where folks aren't able to get care easily and affordably. It's a great model that we need to continue to expand on. If anything, I view some of the, you know, commentary in the report as a tailwind for us. The report's pushing for more services to be done in the home, and each and every one of our health plan clients is looking to do the same, right? More condition management, more engagement to help make sure that we're driving better health outcomes for the members' lives that they serve. Yeah. I think people misunderstood how this report would actually impact us. We view this actually as an opportunity, as Kyle mentioned. You know, just to reiterate, you know, getting them rescheduled back to their PCP, connecting them to community resources, making the referrals to the healthcare management groups, these are all things we're doing today and plan to do more of in the future. Got it. Thanks so much for that. Appreciate it. Yep. Thanks, Michael. Our next question is from George Hill at Deutsche Bank Securities. Please go ahead. Yeah. Good morning, guys, and thanks for taking the question. Kyle, I actually wanna follow up on Michael's line of questioning, which is really, I guess, is there anything more that you guys can do to highlight the, you know, I loved your quote, the absent moral hazard line about the services that you're providing in the HCS segment. I'd say both kind of as a way to differentiate, like, show that there's a real arm's-length transaction between you guys and the MCOs and the carriers, and that there's a real value to using a third-party provider, just because I think it'd be very helpful both for the business growth and for the stock price. I guess just, I'll throw a quick follow-up in there for Steve. You know, as we read a lot about the Great Resignation, I guess, can you talk about how you're thinking about kinda labor inflation and employment and kinda just like the number of people that you have in the field as we're seeing kind of a very tumultuous employment environment and how that kinda impacts margins as we think about 2022? Yeah. I'll take it first, and then Steve can touch on your second question. Yeah, the moral hazard piece is important. I mean, let's start from the top. You know, first and foremost, these visits. Folks are selecting into Medicare Advantage, seniors on their own, right? Like, they're choosing to go into the program, and then they choose to receive these visits, which is free healthcare in their home. It's a pretty amazing value proposition. What we've been excited about is that we have been focused on providing those, all of our services as a flat fee to the health plans, regardless of the work that we do inside. You're right, it's an arm's-length transaction that gives the health plan and the member peace of mind that we're going in to do genuine, high-quality diagnostic work and then ensuring that we're connecting them back to care. It's why we're not using home health workers to do this work. We're using medical doctors and top of the license nurse practitioners, you know, as we're going into these homes. It's a real opportunity to see healthcare where it really happens, which is inside the home, right? We're spending 20 minutes going through their medications that they often can't afford and helping them to figure out better ways to make those meds more affordable for them by connecting them back to benefit services that the plans offer. We're contacting their primary care doctors for them, sending their medical information to the primary care doctors so they can see that they're not taking their meds, or that they have a transportation issue, or that their chronic condition has gone completely unmanaged and their A1C level's through the roof, right? All of that being done as a free benefit to these members in MA is really something that's special and something that we need to be leaning more in as a country, I think, across other populations, which is why we're excited to see our service model pretty dramatically expand into Medicaid and into commercial populations as well. The plans are leaning in, and almost all of them, you know, have home access and expansion of home services as a core differentiator for the current and future state of their businesses. We're a key partner driving that success for them. Secondarily, something that's really important, our year-over-year rebooking rate is very high, and members see extreme value in us coming in and helping, again, to solve problems where, again, healthcare really happens inside their homes, right? We're able to lay eyes on their broader social, clinical, and behavioral environment, and then provide all of that information back in a safe, secure way to the plan and to their primary care doctors. Finally, just on the moral hazard piece, our doctors and nurses do not code, right? They go in and do a totally focused clinical evaluation of the individuals' lives that they touch. We have a totally separate team that goes through and does the coding and any documentation work related to the visit. I'm super proud to say that team has consistently quarter-over-quarter, year-after-year, had a 98-99%+ positive audit rate on all of the work that we do. We are delivering a highly compliant, super valuable touch point that's having a very positive impact on millions of seniors, many of who are in dramatic need, lives throughout the country. I appreciate the question, George. I think that, you know, to answer your you know, the second point about the stock price and everything else, I mean, we're focused on consistent delivery and execution, and we are more bullish than ever on the value that we deliver to seniors and to folks in Medicaid and commercial, and the deep connectivity we have with our plans who are asking us, each and every one of them, to expand our services, you know, in the home and to better connect to these members' lives. Steve, why don't you take those? Yeah, you know, back to the employment situation. You know, our network, as I mentioned earlier, continues to be strong, 9,000+. As we look across the company, we are spending a lot of time as a management team focusing on engagement, making sure this is a great place to work, both virtually and safely back in the office when appropriate. We spend a lot of time talking about the mission of the company, and we start off our meetings with a lot of mission moments. You know, a lot of that stuff goes a long way of really being excited to work for the company that you have, that we're at. You know, like everyone, we have challenges, but as I mentioned in my previous comment, we still expect next year, even with a lot of the noise around labor and pressure to continue to expand our margins. It's again back to our model, as we continue to scale, we will see margin expansion. Thanks, guys. Yeah. Thanks, George. Our next question comes from Sarah James at Barclays. Please go ahead. Thank you. I was hoping that you could kind of level set us on how you think about seasonality of earnings. What were some of the unusual items that impacted this year, and how do you see typical seasonality laying out? Well, the typical seasonality is for the HCS business. You're typically gonna have a stronger first half, and in the back half of the year, it's gonna be a little bit softer because as you go through the list, the member list and get the in-home engagements, that starts to trickle down in the back half of the year, Q4. As we've said since we had the IPO and the roadshow is always our softest quarter. You know, there's a variety of reasons for that. We're winding down the list. There's holidays, the weather, typically. You know, we start again for the following year. That's the biggest thing. In the ECS business, you know, the only things that are a little bit different there is typically when we get the recons in Q2 and Q4, you know, there could be some true ups there that would give it a bump, and then we've got the thirteenth month extra month that gets booked there the way the revenue recognition works. So other than that's probably the quickest way to explain our seasonality. Got it. Thinking through the headwinds and tailwinds that you mentioned for 2022 so far, it seems like there might be a little bit more headwinds in the beginning of the year, tailwinds in the end of the year. Is that the right way to think about the shift in seasonality in 2022 versus a typical year? No, look, I think there's nothing in 2022 that I would see any different, that we would, you know, start off. You know, strong again on the IHE front. We're gonna have all our new lifts and we'll go at it. We'll have the higher program size to start the year with the exit run rate at $6 billion. You know, 2022 should be off to a strong start. It should be a typical seasonality year where, you know, first half's a little stronger than the back half and Q4 would be the softest quarter. Great. Thank you. As a reminder to submit any further questions, please press star one on your telephone keypad. Our next question is from Sean Wieland at Piper Sandler. Please go ahead. Thank you. Good morning. You touched briefly on the possibility of mandatory bundle payments. Wanted to get your perspective on, for your business, is that a good thing or a bad thing, considering CMS might play a greater role as the convener? Hey, Sean, good to hear from you. Yeah, ironically, we had a great call yesterday with almost all of our very large BPCI-A participants talking just about this subject and just future of the program, et cetera. I've got some good perspective from the field. I would say two things. One, we've had, as I kinda mentioned on the script, great consistent engagement with CMS. They are focused, I would say threefold on the future of the program. One, they wanna get more into specialty care, and so that's up, you know, upstream from where we are today, whereas we operate predominantly in the post-acute. That's helping to make site of care decisions on where you're going to get your knee surgery done or get your heart valve replaced, et cetera, versus just the discharge moment. That's a great opportunity for us. That's everything that we've been doing out in the non-BPCI-A bundle space. That's number one. Number two, they are looking at, and we're having frequent meetings with them about the expansion into chronic condition inclusion into the bundles as well, which obviously increases potential program size dramatically because a lot of spend is associated with chronic condition management. Finally, on the future of mandatory, and I would also lump in there the overlap with ACO is another a big focus point for them. I would say that, they've been consistent that they want better engagement between ACO and bundled payments in the future, so, more understanding of, attribution. Largely that's because they're focused on a mandatory. I believe, this is my speculation, probably a voluntary component as well. I would say almost all of the big health systems we had on, and hospitalist PGP groups yesterday on our client advisory board all agree with what I just said. We play the role as convener sometimes and often don't play the role as convener with others. We're an analytics and data and then service company that helps, you know, manage the post-acute today. The status of being a convener or not is not critical to our future in the program. Well, would be the direct answer to your question. Our model is flexible to work with folks regardless who is convening. I think we add a lot of value convening today and have helped, I deeply believe, push forward all the great success that we've seen in BPCI-A across the country. We don't view that as a headwind to us if that was to shift in direction longer term. Does that answer your question? Okay. Yes, that does. Thank you. You also mentioned, in your prepared remarks, the NCQA HEDIS certification. Is that new? Is that an expansion of the addressable market? What are your thoughts there? Yeah, absolutely. Yeah, great question. Thank you for picking up on it. My clinical quality team will be thrilled. We have a great team there. Jennifer Cobb, our leader, who's really leaned in and taken, you know, that bull by the horns. I would say one of the big macro trends inside the health plans, and this goes to my earlier comments, the risk in quality and clinical groups have all started to merge together. Many of our clients are like, "Hey guys, you're in hundreds of thousands of, if not approaching 1 million of our members' homes, we need you to be doing more." The quality teams have really leaned in and, we've worked in concert with them to start to bring in more quality-centric gaps and care, device, you know, work into the home. Just to be clear, a lot of that work has nothing, as I mentioned before, to do with risk adjustment, but it's more focused on gaps in care closure, et cetera. We wanna do that at the highest possible standard. NCQA obviously is the platinum standard in the industry. It's helping us get HEDIS certification and other work. We're doing this in concert by opening up this totally new avenue of doing more of this gaps in care closure inside the home. Some plans are even pushing us towards just gaps in care visits into the future with different populations. It is an expansion opportunity, Sean, and one that we're very excited about. Awesome. Thanks, Kyle. Yeah, great to hear from you. Our next question is from Matt Larew at William Blair. Please go ahead. Yeah, hi, good morning. Wanted to follow up on your comments around service line extensions, things like med management. How much of that do you see as capabilities that you feel you have today, but maybe just need to figure out payment structures versus capabilities that you could expand to either through in-house technology development or M&A? Yeah, great question, Matt. I would say it's on med management, chronic condition management. We have great capabilities today, so I'll touch on those two first. On the med side, the largest percentage of time we spend in the home is helping seniors understand their medications. It is, it's frankly frequently a mess, right? They don't understand the pills they're taking, med-med interactions. This pill makes me nauseous, and I, you know, don't have enough money to afford food necessarily to eat with this type of pill like the doctor recommended. Working through all of that is such a big part of what we do. The plans also have comprehensive med reviews, MTM services, and connection back to their PBM workflow. We're in talks of expanding into all of that, given that great, rich, really golden med list that we're producing, outside of the home with all of the surrounding social, financial, whatever they may be issues. We are in the catbird seat, I think, to make a real positive impact for seniors, to get their meds cleaned up once and for all. This is a plague, across the senior population today, and I think Signify is in a great position to make a positive impact there. That's well underway. We've been doing a lot of work there, and it'll be a great expansion opportunity for us next year. On the chronic condition management side, it's a big synergy between the two businesses. What we've been building out for years now on the Episodes of Care division is the ability to manage chronic conditions for a period of time to get them back in check, right? With clinicians, social workers, you know, all of the patient identification work we do. We are now wanting to bring that capability set more into the home. We already do all the identification work, obviously, on the chronic condition. What we wanna push forward into, and we're in talks with, you know, numerous plans on how to best pilot this, is to go in and pick diabetes, chronic heart failure, some of these conditions that really are plaguing seniors and making a positive impact, connecting them back to caregivers, taking on some risk ourselves as a part of that. I would say that's more in the pricing, figuring out how to do, the med economics and the actuarial analysis. On the remote patient monitoring front, we're doing a lot of that today telephonically. As a part of our transition to home services, we're spending a lot of time engaging and making sure that we're monitoring folks remotely. I think there's an opportunity to expand our device hub and tie more, passive remote patient monitoring, excuse me, work, inside the home as well. CMS recently approved a pretty dramatic expansion of fee-for-service billing on the RPM side, Remote Patient Monitoring side. That's an opportunity for us, obviously, as BPCI-A is a big fee-for-service population. I think that the Medicare Advantage plans are leaning in here, too. We're in a great position to activate and to monitor and provide follow-on services as a result of that reach in the home. So we're pretty excited, you know, about that roadmap. And I think that, you know, as I characterized earlier, what are the plans asking us to do more of? It falls into that bucket of work, I would say, more than anything. The final thing that you'll see continued, you know, innovation from us, we're spinning up a team that's focused just on deeper connections back to primary care and to specialists out of the home as well. We've been doing that for years, but we're now wanting to dig in more, using our core data platform and assets to push information via our FHIR APIs, push digital scheduling, and we view ourselves as a big activation hub to really get folks more engaged in their care. The plans are super excited about that innovation from us as well. I mean, getting folks back to, you know, their care providers, it lowers readmissions, it allows them to have more happy, healthy days at home, which is our mission, and it's something that we're laser focused on next year as well. Thanks for the question, Matt. Yeah, thanks a lot, Kyle. That's really helpful. One thing I wanna follow up on from your comments, you mentioned that some of the IHE strength this year, next year is related to, you know, not the share taking, but more movement from in-house volume. I'm curious, you know, the OIG report perhaps wasn't applicable to you and the services you provide, but we're wondering if you think it's changed the thought process or kind of the risk calculus that payers are going through as they consider in-house versus third-party, IHEs. Yeah. I think that it really plays into this arm's length, you know, moral hazard thing. They, you know, you wanna have a completely independent, highly compliant, 99% plus audited, you know, partner to help you deliver these super critical services and number one. Number two, I mean, we have the best data asset and the best logistics and routing platform to be able to pull this off at nationwide scale. They're consistently seeing this. We saw several of our large and medium and small clients expand their programs, number one, so move this to more members 'cause they're seeing all of the benefit of positive outcomes to those members, number one. Number two, we saw the sunsetting and move away from several in-source programs. I deeply believe we have no real risk of in-source, which is always, you know, something that folks say inside payer services businesses. Why wouldn't they just in-source themselves? I think our payer clients, we have extremely strong relationships with them, and it would be nearly impossible, I believe, for them to stand up nationwide scale like we have. It's been fantastic. Instead, conversations focused on, "Hey, guys, we need you to do more in the home. Like, we wanna drive more of an impact." And as I've kinda mentioned, you know, extensively in the call, we want deeper and deeper engagement from you all because you've got a really trusted relationship with these folks. Like, what's more trust than allowing a clinician to come inside your home, right? Spend, you know, an hour with you trying to solve some really complex health problems. There's more work we could be doing on benefit explanation and connecting them to, you know, other programs that the plans are running and pushing forward on the supplemental benefit side, too, is something we've talked a lot about. I do think we're gonna continue to see an expanded TAM by moving into, as I mentioned, Medicaid and commercial and touching more and more Medicare Advantage lives, number one. Number two, we see no risk in the foreseeable future of insourcing. In quite the contrary, folks are leaning in more than ever and asking Signify to do more than ever to make a positive impact on these individuals' lives that we're touching. Yeah, makes a lot of sense. Thanks for all the great detail, Kyle. Yeah. Thanks, Matt. We appreciate it. As we have no further questions on the call, I will hand back to Kyle to conclude. Great. Thank you all very much for a wonderful quarter, and thanks to the whole team for leaning in. It's been amazing to see us dive into more homes, as I mentioned, expand our services. We're very, you know, bullish on the expanded program size and seeing episodes continue to drive positive outcomes, both for the BPCI-A population, as well as the Episodes of Care, the non-BPCI-A population. Thank you all very much, and we'll talk to you guys all soon. Take care. This concludes today's conference call. Thank you all for joining. You may now disconnect your lines.